8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

Solid Tumor Responses – Cell Recruitment, Engagement & Overcoming Immunosuppressive Environment Factors

9:00 am CYT-303 is a Novel Mutispecific NKp46 NK Cell Engager Against GPC3 Expressing HCC Tumors that Mediates Potent Tumor Killing and Reverses NK Cell Dysfunction in the Tumor Microenvironment

  • Tony Arulanandam Senior Vice President & Head of Preclinical Research & Development, Cytovia Therapeutics


  • CYT-303 NK cell engager mediates potent HCC tumor killing via NK cell redirected killing, antibody-dependent macrophage phagocytosis (ADCP), and complement-mediated cytotoxicity (CDC)
  • CYT-303 reverses NK cell dysfunction observed in the HCC tumor microenvironment in serial killing and hypoxia and TGF-beta-mediated immunosuppressive states
  • CYT-303 shows potent dose-dependent anti-tumor activity in humanized HCC subcutaneous tumor models correlating with increased NK infiltration of tumors and reductions in blood AFP biomarkers
  • Based on the efficacy, pharmacokinetics, and safety profile of CYT-303, Cytovia is planning to initiate Phase 1 clinical trials in HCC patients

9:30 am In Vitro and In Vivo Studies Establish DuoBody®-CD3xB7H4 as a Novel Drug Candidate for The Treatment Of Solid Cancers


  • DuoBody®-CD3xB7H4 is an Fc-silenced bispecific antibody designed to induce T-cell mediated cytotoxicity of B7H4+ tumor cells
  • Preclinical and PD biomarker studies suggest DuoBody-CD3×B7H4 enhances T-cell activation, proliferation, and production of cytokines and effector molecules
  • DuoBody®-CD3xB7H4 is currently being investigated in a first-in-human trial for the treatment of solid tumors known to express B7H4

10:00 am Speed Networking & Morning Break


A session dedicated to taking advantage of face-to-face networking time. This an exciting opportunity to get an understanding of who else is overcoming similar challenges within the cell engager space.

11:00 am Roundtable Discussion: Strategy Analysis for Greater Solid Tumor Penetration & More Durable Tumor Killing


At your table, each attendee will have an opportunity to describe and explain one strategy for improving solid tumor responses. This can be based on:

  • Your company’s public information
  • Or your own belief based on the data that you are currently aware of

Following the discussion, we will take 5 minutes for you to engage in debate about the strategies that have been laid out. Your goal will be to pull from this discussion a key learning point that you believe to be unique or particularly important. Finally, we will ask you to write down your key learning(s) which will be collected, compiled, and then released as a post-event report.

11:30 am Improving CD19-targeting T Cell Engagers: The Example of CLN-978

  • KRISTAN MEETZE Vice President, Preclinical and Early Development, Cullinan Oncology.


  • A very high-affinity CD19-binding antibody fragment allows targeting lymphoma and leukemia cells expressing very low target levels
  • An albumin-binding single-domain antibody is used as a means to significantly extend serum half life
  • Subcutaneous injection of CLN-978 is a means to significantly lower initial exposure and curb cytokine release

12:00 pm Engaging Immune Cells To Fight Cancer – Clinical Updates Of Mono- And Combination Therapies

  • Joachim Koch Vice President & Head Discovery Research & Translational Immunology, Affimed GmbH


  • Demonstrate broad applicability of the mechanism of action of Affimed’s ICE® molecules to multimodal therapies of hematological and solid cancers
  • Share Affimed’s data record and vision of how synergies of innate and adaptive immunity can be leveraged to fight cancer
  • Update on AFM24 clinical and correlative science data

12:30 pm Networking & Lunch Break

1:30 pm Challenging the Predictability of Preclinical Models for Assessment of Cell Engagers

  • Kader Thiam Senior Vice President - Discovery, Preclinical Models & Services, GenOway


  • Focus on BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments and syngeneic humanized mouse model
  • Characterization of the immune response in these mice
  • Assessment of efficacy and irAE induced by cell engagers

2:00 pm Achieving Strong Avidity & Durability


  • Utilizing the natural features of immunoglobulins to achieve strong binding
  • Looking into the overall developability strengths and weaknesses of IGM based modalities

2:30 pm Development of Novel TriTACs


  • T cell-engaging therapeutic proteins optimized with the potential to increase the therapeutic index
  • Treating of hematologic and solid tumors

3:00 pm A Next Generation Mathematical Model for the In Vitro to Clinical Translation of T-cell Engagers


  • Regulatory agencies recommend more quantitative justifications for clinical dose selection, especially for bispecific T-cell engagers (TCE) which form a “trimer” and which serve as a proxy for TCE activity
  • We present a next-generation mathematical model for TCEs where the key step in trimer formation is sensitive to the cell-surface density of TCE targets, rather than receptor concentration
  • This model is robust to common variances between experimental and clinical conditions which commonly make traditional models less accurate

3:30 pm Afternoon Coffee Break & Poster Session


Join your peers in the cell engager field by presenting your work in our dedicated cell engager poster session. This is the perfect opportunity to discuss, debate, and display your work in the field.

Finding the Right Tools for the Job & Refining Them to Your Needs: Targets, Engagers & Costimulators

4:00 pm Tumor-Targeted Antibody-Anticalin Bispecifics as Potent Costimulatory Molecules


  • Novel costimulators facilitate the generation of multispecific protein formats addressing specific biological modalities
  • Robust and highly selective Anticalin® proteins serving as agonists of costimulatory receptors like 4-1BB
  • Mabcalin™ proteins leverage receptor engagement in immuno-oncology by rational combination with precision targeting

4:30 pm Albumin-Based Biomolecular Multispecifics Designs

  • Ken Howard Associate Professor, Aarhus University

5:00 pm Chair’s Closing Remarks

5:10 pm End of Conference Day One